诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09969 诺诚健华

交易中 07-23 14:16:59

4.630

-0.030

-0.64%

最高4.670	最低4.600	成交量37.20万
今开4.650	昨收4.660	日振幅1.50%
总市值81.68亿	流通市值81.68亿	总股本17.64亿
成交额172.22万	换手率0.02%	流通股本17.64亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":4.63,"timestamp":1721715283090,"preClose":4.66,"halted":0,"volume":372000,"delay":0,"floatShares":1764217202,"shares":1764217202,"eps":-0.39633408,"marketStatus":"交易中","marketStatusCode":2,"change":-0.03,"latestTime":"07-23 14:16:59","open":4.65,"high":4.67,"low":4.6,"amount":1722170,"amplitude":0.015021,"askPrice":4.63,"askSize":46000,"bidPrice":4.61,"bidSize":47000,"shortable":3,"etf":0,"ttmEps":-0.442941893915501,"exchange":"SEHK","tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1721722200000},"adr":0,"listingDate":1584892800000,"adjPreClose":4.66,"openAndCloseTimeList":[[1721698200000,1721707200000],[1721710800000,1721721600000]],"volumeRatio":0.049599,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":8.93,"timestamp":1721715365000,"preClose":9.1,"halted":0,"volume":2649499,"delay":0,"premium":"-51.60"}},"requestUrl":"/m/hq/s/09969","defaultTab":"news","newsList":[{"id":"2453731561","title":"诺诚健华奥布替尼多项研究入选2024年欧洲肿瘤内科学会（ESMO）年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2453731561","media":"证券日报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453731561?lang=zh_cn&edition=full","pubTime":"2024-07-22 14:22","pubTimestamp":1721629376,"startTime":"0","endTime":"0","summary":"本报讯（记者李乔宇）7月22日，生物医药高科技公司诺诚健华（上交所代码：688428；香港联交所代码：09969）宣布，新型BTK抑制剂奥布替尼的五项研究入选2024年欧洲肿瘤内科学会（ESMO）年会，其中奥布替尼治疗初治边缘区淋巴瘤的前瞻性研究入选此次大会的口头报告。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202407223136759712.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1574","09969"],"gpt_icon":0},{"id":"2452616932","title":"Vivo Capital减持诺诚健华：或套现1.88亿港元 仍是重要股东","url":"https://stock-news.laohu8.com/highlight/detail?id=2452616932","media":"雷递网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452616932?lang=zh_cn&edition=full","pubTime":"2024-07-20 20:24","pubTimestamp":1721478242,"startTime":"0","endTime":"0","summary":"雷递网 雷建平 7月20日诺诚健华医药有限公司日前发布公告，宣布重要股东Vivo Capital进行减持，减持了诺诚健华2.27%股权。此次减持后，Fund VIII持股为4.24%，Surplus Fund VIII持股为0.58%，Fund IX、Opp Fund、Asia Opp Fund、Co-Invest Fund均不再持股。截至昨日收盘，诺诚健华股价为4.71港元，市值为83.09亿港元。若以收盘价计算，Vivo Capital可能套现1.88亿港元。诺诚健华2024年第一季度营收为1.66亿元，同比下降12.44%；净亏损为1.42亿元，扣非后净亏损为1.34亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407202024319f719676&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407202024319f719676&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","688428","09969"],"gpt_icon":0},{"id":"2452295264","title":"诺诚健华(09969)股东Fund VIII、Opp Fund等合计减持4016.9万股公司股份 持股比例降至 4.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452295264","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452295264?lang=zh_cn&edition=full","pubTime":"2024-07-19 18:55","pubTimestamp":1721386517,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(09969)公布，公司于近日收到公司股东 Fund VIII、Surplus Fund VIII、Opp Fund、Fund IX、Asia Opp Fund、CoInvest Fund 发来的《诺诚健华医药有限公司简式权益变动报告书》。Fund VIII、Surplus Fund VIII、Opp Fund、Fund IX、Asia Opp Fund、CoInvest Fund 于2024年7月17日合计减持4016.9万股，持股数量减少至约8505.31万股，持有股份占公司已发行总股数的比例从 7.09%减少至 4.82%，不再是公司持股 5%以上的股东。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153361.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","09969","BK0239","688428","BK1574"],"gpt_icon":0},{"id":"2452493540","title":"诺诚健华盘中异动 大幅下跌5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452493540","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452493540?lang=zh_cn&edition=full","pubTime":"2024-07-19 09:32","pubTimestamp":1721352728,"startTime":"0","endTime":"0","summary":"2024年07月19日早盘09时32分，诺诚健华股票出现波动，股价大幅下跌5.10%。截至发稿，该股报4.470港元/股，成交量47.1935万股，换手率0.03%，振幅5.10%。诺诚健华股票所在的生物技术行业中，整体跌幅为0.45%。其相关个股中，宜明昂科-B、中国抗体-B、金斯瑞生物科技涨幅较大，振幅较大的相关个股有宜明昂科-B、诺诚健华、金斯瑞生物科技，振幅分别为8.22%、5.10%、3.13%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407190932099681e2d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407190932099681e2d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","09969","688428"],"gpt_icon":0},{"id":"2452464019","title":"诺诚健华发行合计163.5万股人民币股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2452464019","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452464019?lang=zh_cn&edition=full","pubTime":"2024-07-19 08:22","pubTimestamp":1721348553,"startTime":"0","endTime":"0","summary":"诺诚健华（09969）发布公告，于2024年7月18日，根据2023年科创板限制性股票奖励计划首次授予部分第一个归属期的归属结果向2名董事及86名激励对象发行合计163.5万股人民币股份。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-07-19/doc-incermif1180967.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-07-19/doc-incermif1180967.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1161","BK1574","09969"],"gpt_icon":0},{"id":"2452107985","title":"诺诚健华(09969)发行合计163.5万股人民币股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2452107985","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452107985?lang=zh_cn&edition=full","pubTime":"2024-07-18 19:36","pubTimestamp":1721302581,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(09969)发布公告，于2024年7月18日，根据2023年科创板限制性股票奖励计划首次授予部分第一个归属期的归属结果向2名董事及86名激励对象发行合计163.5万股人民币股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688428","09969","BK1161","BK1574"],"gpt_icon":0},{"id":"2452872176","title":"诺诚健华盘中异动 临近收盘大幅下跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452872176","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452872176?lang=zh_cn&edition=full","pubTime":"2024-07-18 15:45","pubTimestamp":1721288724,"startTime":"0","endTime":"0","summary":"2024年07月18日临近收盘15时45分，诺诚健华股票出现异动，股价大幅下跌5.00%。截至发稿，该股报4.750港元/股，成交量4501.1万股，换手率3.00%，振幅5.00%。机构评级方面，在所有5家参与评级的机构中，80%的券商给予买入建议，20%的券商给予持有建议，无券商给予卖出建议。诺诚健华股票所在的生物技术行业中，整体涨幅为0.13%。诺诚健华公司简介：诺诚健华医药有限公司是一家主要从事生物医药研发、生产和商业化的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240718154524aefa4698&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240718154524aefa4698&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","688428","BK1574","09969"],"gpt_icon":0},{"id":"2452274176","title":"诺诚健华(09969)下跌5.0%，报4.75元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2452274176","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452274176?lang=zh_cn&edition=full","pubTime":"2024-07-18 15:45","pubTimestamp":1721288722,"startTime":"0","endTime":"0","summary":"7月18日，诺诚健华(09969)盘中下跌5.0%，截至15:45，报4.75元/股，成交2.07亿元。诺诚健华医药有限公司是一家拥有一体化生物医药平台的领先企业，主要从事研发治疗癌症和自身免疫性疾病的创新药物。公司具备强大的内部研发能力和世界级管理团队，同时拥有均衡的管线组合和针对经过验证或新颖生物通路的候选药物。截至2024年一季报，诺诚健华营业总收入1.66亿元、净利润-1.42亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/18154541645432.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","688428","BK1574","09969","BK0239"],"gpt_icon":0},{"id":"2452788361","title":"诺诚健华发布2024年度“提质增效重回报”行动方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2452788361","media":"证券日报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452788361?lang=zh_cn&edition=full","pubTime":"2024-07-18 14:56","pubTimestamp":1721285779,"startTime":"0","endTime":"0","summary":"本报讯（记者向炎涛）7月18日，诺诚健华发布2024年度“提质增效重回报”行动方案。公司将在研发创新、财务管理、公司治理及投资者关系等方面采取积极措施，以进一步提高公司质量，维护全体股东权益，促进公司健康可持续发展。2024年，诺诚健华将持续加大研发投入，持续丰富管线并推进管线内产品的临床及商业化进程，进一步加强全球研发能力、商业化体系建设，提升生产能力及质量体系建设。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202407183134403426.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","09969","BK1574"],"gpt_icon":0},{"id":"2452814939","title":"诺诚健华发布2024年度“提质增效重回报”行动方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2452814939","media":"证券市场周刊","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452814939?lang=zh_cn&edition=full","pubTime":"2024-07-18 10:02","pubTimestamp":1721268149,"startTime":"0","endTime":"0","summary":"奥布替尼在国内已获批3项适应症并均已纳入医保，销售额持续快速增长。此外，诺诚健华不断优化财务管理，提高经营效率；积极提升公司治理水平，提高上市公司质量；提高信息披露质量，加强投资者沟通交流。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071810052595d2694b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071810052595d2694b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688428","BK0239","09969"],"gpt_icon":0},{"id":"2451139636","title":"诺诚健华07月15日主力资金流入36万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2451139636","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451139636?lang=zh_cn&edition=full","pubTime":"2024-07-15 16:15","pubTimestamp":1721031316,"startTime":"0","endTime":"0","summary":"07月15日, 诺诚健华股价跌3.36%，报收4.89元，成交金额827万元，换手率0.11%，振幅3.56%，量比0.47。诺诚健华今日主力资金净流入36万元，连续3日净流入，上一交易日主力净流入145万元，今日环比减少75.17%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为50.00%，平均涨幅为1.18%。该股近5个交易日上涨6.30%，主力资金累计净流入279万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入662万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407151615419f4da38a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407151615419f4da38a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","09969"],"gpt_icon":0},{"id":"2450829588","title":"诺诚健华(09969)：163.475万股A股将于7月18日上市流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2450829588","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450829588?lang=zh_cn&edition=full","pubTime":"2024-07-12 18:42","pubTimestamp":1720780923,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(09969)发布公告，根据中国证券监督管理委员会、上海证券交易所、中国证券登记结算有限责任公司上海分公司相关规定，该公司于近日收到中国证券登记结算有限责任公司上海分公司出具的《证券变更登记证明》，公司完成了2023年科创板限制性股票激励计划(以下简称“本激励计划”)首次授予部分第一个归属期的股份登记工作。本次A股股票上市流通总数为163.475万股。本次A股股票上市流通日期为2024年7月18日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1150204.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09969","BK1161","399300","BK0239","BK1574","159982","688428"],"gpt_icon":0},{"id":"2450347109","title":"港股异动 | 医药股再度走高 行业投融资有望触底回暖 创新药政策释放积极信号","url":"https://stock-news.laohu8.com/highlight/detail?id=2450347109","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450347109?lang=zh_cn&edition=full","pubTime":"2024-07-12 09:56","pubTimestamp":1720749399,"startTime":"0","endTime":"0","summary":"消息面上，美国6月CPI超预期放缓，9月降息概率冲至近90%。太平洋证券指出，未来随着美联储加息周期结束，流动性逐步宽松有望带来投融资回暖，海外需求将先于本土需求改善。此外，《全链条支持创新药发展实施方案》近期出台释放积极信号。东吴证券认为，具体条款有望近期落地，叠加创新药板块处于历史相对底部位置，下半年有ESMO大会、WCLC大会、医保谈判、创新药出海预期等多重催化，创新药板块有望走强。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1149802.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","HK0000320223.HKD","HK0000320264.USD","09939","BK1161","159992","BK1141","BK1576","HSCEI","BK1588","06978","YANG","BK1583","159938","HSTECH","LU0196878994.USD","06990","01548","BK1515","09688","HK0000306685.HKD","HK0000306701.USD","07226","09969"],"gpt_icon":0},{"id":"2450342900","title":"诺诚健华盘中异动 早盘快速上涨5.20%报5.060港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450342900","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450342900?lang=zh_cn&edition=full","pubTime":"2024-07-12 09:41","pubTimestamp":1720748495,"startTime":"0","endTime":"0","summary":"2024年07月12日早盘09时41分，诺诚健华股票出现波动，股价大幅拉升5.20%。截至发稿，该股报5.060港元/股，成交量67.8万股，换手率0.05%，振幅4.16%。资金方面，该股资金流入202.365万港元，流出92.25万港元。机构评级方面，在所有5家参与评级的机构中，80%的券商给予买入建议，20%的券商给予持有建议，无券商给予卖出建议。诺诚健华股票所在的生物技术行业中，整体涨幅为0.30%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407120941359681c2be&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407120941359681c2be&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688428","BK0239","09969"],"gpt_icon":0},{"id":"2449723797","title":"7月8日诺诚健华-U跌6.01%，鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2449723797","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449723797?lang=zh_cn&edition=full","pubTime":"2024-07-08 16:12","pubTimestamp":1720426348,"startTime":"0","endTime":"0","summary":"证券之星消息，7月8日诺诚健华-U跌6.01%，收盘报8.45元，换手率2.15%，成交量5.53万手，成交额4783.72万元。重仓诺诚健华-U的公募基金请见下表：该股最近90天内共有4家机构给出评级，买入评级2家，增持评级2家；过去90天内机构目标均价为13.9。根据2024基金Q1季报公募基金重仓股数据，重仓该股的公募基金共7家，其中持有数量最多的公募基金为鹏华医药科技股票A。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070800020166.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159938","BK1574","09939","688428","BK1515","09969","BK1161"],"gpt_icon":0},{"id":"2449712662","title":"诺诚健华(09969)下跌5.26%，报4.68元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2449712662","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449712662?lang=zh_cn&edition=full","pubTime":"2024-07-08 11:46","pubTimestamp":1720410387,"startTime":"0","endTime":"0","summary":"7月8日，诺诚健华(09969)盘中下跌5.26%，截至11:46，报4.68元/股，成交502.35万元。诺诚健华医药有限公司是一家拥有一体化生物医药平台的领先企业，主要从事研发治疗癌症和自身免疫性疾病的创新药物。公司具备强大的内部研发能力和世界级管理团队，同时拥有均衡的管线组合和针对经过验证或新颖生物通路的候选药物。截至2024年一季报，诺诚健华营业总收入1.66亿元、净利润-1.42亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/08114641426609.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","BK0239","09969","688428","BK1574"],"gpt_icon":0},{"id":"2449717555","title":"诺诚健华盘中异动 临近午盘快速下跌5.06%报4.691港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2449717555","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449717555?lang=zh_cn&edition=full","pubTime":"2024-07-08 11:46","pubTimestamp":1720410380,"startTime":"0","endTime":"0","summary":"2024年07月08日临近午盘11时46分，诺诚健华股票出现异动，股价快速跳水5.06%。截至发稿，该股报4.691港元/股，成交量105.1万股，换手率0.07%，振幅5.67%。资金方面，该股资金流入163.997万港元，流出293.1万港元。诺诚健华股票所在的生物技术行业中，整体跌幅为1.44%。诺诚健华公司简介：诺诚健华医药有限公司是一家主要从事生物医药研发、生产和商业化的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407081146209681a7d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407081146209681a7d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","BK1574","688428","BK1161"],"gpt_icon":0},{"id":"2449712015","title":"诺诚健华(09969)股价下跌5.061%，现价港币$4.69","url":"https://stock-news.laohu8.com/highlight/detail?id=2449712015","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449712015?lang=zh_cn&edition=full","pubTime":"2024-07-08 11:46","pubTimestamp":1720410360,"startTime":"0","endTime":"0","summary":"[下跌股]诺诚健华(09969) 股价在上午11:46比前收市价下跌5.061%，现股价为港币$4.69。至目前为止，今日最高价为$4.96，而最低价为$4.69。总成交量为99.2万股，总成交金额为港币$474.622万。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180416150425748_s.png","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180416150425748_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2407081669/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","BK1161","BK0239","688428","09969"],"gpt_icon":0},{"id":"2448411033","title":"诺诚健华07月04日遭主力抛售16万元 环比增加700.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2448411033","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448411033?lang=zh_cn&edition=full","pubTime":"2024-07-04 16:15","pubTimestamp":1720080929,"startTime":"0","endTime":"0","summary":"07月04日, 诺诚健华股价跌2.22%，报收4.85元，成交金额983万元，换手率0.13%，振幅3.02%，量比0.57。诺诚健华今日主力资金净流出16万元，上一交易日主力净流出2万元，今日环比增加700.00%。该股近5个交易日上涨2.55%，主力资金累计净流入138万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入538万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407041615459f01dc87&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407041615459f01dc87&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09969","BK1574"],"gpt_icon":0},{"id":"2448936804","title":"长城国瑞证券：给予诺诚健华买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2448936804","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448936804?lang=zh_cn&edition=full","pubTime":"2024-07-04 11:57","pubTimestamp":1720065441,"startTime":"0","endTime":"0","summary":"长城国瑞证券有限公司胡晨曦,魏钰琪近期对诺诚健华进行研究并发布了研究报告《血液瘤产品商业化持续推进，自免管线进展可喜》，本报告对诺诚健华给出买入评级，当前股价为9.01元。最新盈利预测明细如下：该股最近90天内共有3家机构给出评级，买入评级1家，增持评级2家；过去90天内机构目标均价为13.9。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070400021847.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","161027","09969"],"gpt_icon":0}],"profile":{"websiteUrl":"https://cn.innocarepharma.com","stockEarnings":[{"period":"1week","weight":-0.047},{"period":"1month","weight":-0.0189},{"period":"3month","weight":0.1043},{"period":"6month","weight":-0.1738},{"period":"1year","weight":-0.3753},{"period":"ytd","weight":-0.3237}],"compareEarnings":[{"period":"1week","weight":-0.0211},{"period":"1month","weight":-0.0218},{"period":"3month","weight":0.048},{"period":"6month","weight":0.1092},{"period":"1year","weight":-0.0755},{"period":"ytd","weight":0.0345}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"诺诚健华医药有限公司是一家主要从事生物医药研发、生产和商业化的中国公司。该公司专注于肿瘤和自身免疫性疾病等存在巨大未满足临床需求的领域。该公司的主要产品管线包括奥布替尼、伊布替尼、泽布替尼、Tafasitamab、ICP-490、ICP-B02、ICP-248、ICP-192、ICP-723和ICP-189等。其产品主要用于治疗血液瘤、实体瘤和自身免疫病。该公司还在开发用于治疗由B细胞或T细胞功能异常所导致的自身免疫性疾病的产品。该公司主要在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.120109},{"month":2,"riseRate":0.5,"avgChangeRate":0.019126},{"month":3,"riseRate":0,"avgChangeRate":-0.043789},{"month":4,"riseRate":0.6,"avgChangeRate":0.117148},{"month":5,"riseRate":0,"avgChangeRate":-0.072765},{"month":6,"riseRate":0.8,"avgChangeRate":0.122586},{"month":7,"riseRate":0.4,"avgChangeRate":-0.02759},{"month":8,"riseRate":0,"avgChangeRate":-0.125366},{"month":9,"riseRate":0,"avgChangeRate":-0.152637},{"month":10,"riseRate":0.5,"avgChangeRate":0.014569},{"month":11,"riseRate":1,"avgChangeRate":0.145409},{"month":12,"riseRate":0.75,"avgChangeRate":0.038159}],"exchange":"SEHK","name":"诺诚健华","nameEN":"INNOCARE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,09969,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}